XML 35 R20.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Equity Based Plans | 12 Months Ended
--- | ---
Dec. 31, 2021
Equity Based Plans [Abstract] |
Equity Based Plans | 14. Equity Based Plans The Company has the following equity-based plans with outstanding equity grants: The Amended and Restated 1999 Employee Stock Option Plan (the “Amended 1999 Plan”) permits the Company to grant to non-employee directors and employees of the Company up to 600,000 non-qualified options to purchase shares of common stock and restricted stock (subject to proportionate adjustments in the event of stock dividends, splits, and similar corporate transactions). The exercise prices of options granted under the Amended 1999 Plan are determined by the Compensation Committee. The period within which each option will be exercisable is determined by the Compensation Committee. The Amended 1999 Plan was approved by the shareholders of the Company at the 2008 Shareholders Meeting on May 20, 2008. The Amended and Restated 2003 Stock Option Plan (the “Amended 2003 Plan”) permits the Company to grant to key employees and outside directors of the Company incentive and non-qualified options and shares of restricted stock covering up to 2,100,000 shares of common stock (subject to proportionate adjustments in the event of stock dividends, splits, and similar corporate transactions). The material terms of the Amended 2003 Plan was reapproved by the shareholders of the Company at the 2015 Shareholders Meeting on May 19, 2015 and an increase in the number of shares authorized for issuance from 1,750,000 to 2,100,000 was approved at the 2016 Shareholders Meeting on March 17, 2016. A cumulative summary of equity plans as of December 31, 2021 follows:
|  | Authorized |  |  | Restricted Stock Issued |  |  | Outstanding Stock Options |  |  | Stock Options Exercised |  |  | Stock Options Exercisable |  |  | Shares Available for Grant |
Equity Plans |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amended 1999 Plan |  |  | 600,000 |  |  |  | 416,402 |  |  |  | - |  |  |  | 139,791 |  |  |  | - |  |  |  | 7,775 |
Amended 2003 Plan |  |  | 2,100,000 |  |  |  | 1,166,855 |  |  |  | - |  |  |  | 778,300 |  |  |  | - |  |  |  | 164,882 |
|  |  | 2,700,000 |  |  |  | 1,583,257 |  |  |  | - |  |  |  | 918,091 |  |  |  | - |  |  |  | 172,657 |
During 2021, 2020 and 2019, the Company granted the following shares of restricted stock to directors, officers and employees pursuant to its equity plans as follows:
Year Granted |  | Number of Shares |  | Weighted Average Fair Value Per Share |
2021 |  | 60,317 |  | $ | 131.29 |
2020 |  | 86,982 |  | $ | 104.69 |
2019 |  | 91,682 |  | $ | 104.85 |
During 2021, 2020 and 2019, the following shares were cancelled due to employee terminations prior to restrictions lapsing:
Year Cancelled |  | Number of Shares |  | Weighted Average Fair Value Per Share |
2021 |  | 439 |  | $ | 113.80 |
2020 |  | 10,037 |  | $ | 102.52 |
2019 |  | 1,578 |  | $ | 87.88 |
Generally, restrictions on the stock granted to employees lapse in equal annual installments on the following four anniversaries of the date of grant. For those shares granted to directors, the restrictions will lapse in equal quarterly installments during the first year after the date of grant. For those granted to officers, the restriction will lapse in equal quarterly installments during the four years following the date of grant. There were 102,682 and 127,562 shares outstanding as of December 31, 2021 and December 31, 2020, respectively, for which restrictions had not lapsed. The restrictions will lapse in 2022 through 2025. Compensation expense for grants of restricted stock is recognized based on the fair value on the date of grant. Compensation expense for restricted stock grants was $7.8 million, $7.9 million, and $7.0 million, respectively, for 2021, 2020 and 2019. As of December 31, 2021, the remaining $8.9 million of compensation expense will be recognized from 2022 through 2025.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration